Medical Marijuana, Inc. Investment AXIM® Biotech Announces Enrolled Patients Begin Phase II Trial For The …

Final data collection for primary outcome measure is estimated to complete in April 2017, with the full study estimated to complete in June 2017.

“Successfully enrolling patients in this IBS clinical trial, which marks the first advancement in cannabinoid research for treatment of IBS in medical history, is an exciting new milestone for AXIM’s clinical development program,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “With the global treatment market for IBS estimated to grow in value to $1.5 billion by 2023, AXIM’s efforts continue to push forward with cutting-edge solutions to help people suffering from some of the most common gastrointestinal disorders, not only for IBS, but for Irritable Bowel Disease and Ulcerative Colitis as well.”

For more information on the AXIM’s IBS trial, please visit: https://clinicaltrials.gov/ct2/show/NCT03003260

IBS is the most common functional gastrointestinal disorder with a prevalence worldwide ranging from 9-23% and results

... read more at: http://www.prnewswire.com/news-releases/medical-marijuana-inc-investment-axim-biotech-announces-enrolled-patients-begin-phase-ii-trial-for-the-treatment-of-irritable-bowel-syndrome-ibs-with-canchew-plus-cannabidiol-cbd-chewing-gum-300419310.html